Alıntılar

APA (7. basım) Alıntı
John, N., Kalincik, T., Lechner-Scott, J., Hodgkinson, S., Butzkueven, H., Barnett, M., . . . Sharmin, S. (2024). 3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. BMJ Publishing Group.
Chicago Style (17. basım) Atıf
John, Nevin, et al. 3138 Effectiveness of Cladribine Compared to Fingolimod, Natalizumab, Ocrelizumab and Alemtuzumab in Relapsing-remitting Multiple Sclerosis. BMJ Publishing Group, 2024.
MLA (9th ed.) Atıf
John, Nevin, et al. 3138 Effectiveness of Cladribine Compared to Fingolimod, Natalizumab, Ocrelizumab and Alemtuzumab in Relapsing-remitting Multiple Sclerosis. BMJ Publishing Group, 2024.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..